← All trials
NCT05153408
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2021
- Primary completion
- Jun 10, 2024
- Completion date
- Dec 10, 2024
- First posted
- Dec 10, 2021
- Last posted
- Dec 10, 2021
- Enrollment
- 160
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Blueprint Medicines CorporationLead sponsor
Drugs studied
Indications studied
- Adenocarcinoma
- Antineoplastic Agents
- Bronchial Neoplasms
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Non-Small-Cell Lung
- Epidermal Growth Factor
- Lung Diseases
- Lung Neoplasms
- Mutation
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Nerve Tissue
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Protein Kinase Inhibitors
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.